Fragile x Syndrome and Alzheimer's disease: Another story about APP and β-Amyloid

Current Alzheimer Research

Volumn 7, Issue 3, 2010, Pages 200-206

  Malter, J S ^a   Ray, B C ^a   Westmark, P R ^a   Westmark, C J ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Amyloid precursor protein (APP) and beta amyloid; Fragile x syndrome (FXS); Metabotropic glutamate receptors (mGluR)

Indexed keywords

2 METHYL 6 (2 PHENYLVINYL)PYRIDINE; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; AMYLOID BETA PROTEIN; FRAGILE X MENTAL RETARDATION PROTEIN; MESSENGER RNA; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 5;

ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; DOWN SYNDROME; DRUG ANTAGONISM; DRUG EFFECT; DRUG INHIBITION; FRAGILE X SYNDROME; GENETIC TRANSCRIPTION; HUMAN; IMMUNOPRECIPITATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SEIZURE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID ANTAGONISTS; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; GLUTAMIC ACID; HUMANS; PHENOTYPE; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 77952474914     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720510791050957     Document Type: Article

References (59)

1. Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 192(1): 106-13 (2008).
2. Cerpa W, Dinamarca MC, Inestrosa NC. Structure-function implications in Alzheimer's disease: effect of Abeta oligomers at central synapses. Curr Alzheimer Res 5(3): 233-43 (2008).
3. Puzzo D, Privitera L, Leznik E, Fà M, Staniszewski A, Palmeri A, et al. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci 28: 14537-14545 (2008).
4. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27: 2866-75 (2007).
5. Spooren WP, Gasparini F, Salt TE, Kuhn R. Novel allosteric antagonists shed light on mGluR5 and CNS disorders. Trends Pharmacol Sci 22: 331-7 (2001).
6. Kromann H, Sløk FA, Stensbøl TB, Bräuner-Osborne H, Madsen U, Krogsgaard-Larsen P. Selective antagonists at group I metabotropic glutamate receptors: synthesis and molecular pharmacology of 4-aryl-3-isoxazolol amino acids. J Med Chem 45(4): 988-91 (2002).
7. Conn PJ, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37: 205-37 (1997).
8. th. Metabotropic glutamate receptor subtypes 1 and 5 are activators of extracellular signal-regulated kinase signaling required for inflammatory pain in mice. J Neurosci 21: 3771-9 (2001).
9. 2+ and protein kinase C-dependent pathway. J Neurochem 93: 232-245 (2005).
10. Yuan JP, Kiselyov K, Shin DM, Chen J, Shcheynikov N, Kang SH, et al. Homer binds TRPC family channels and is required for gating of TRPC1 by IP3 receptors. Cell 114: 777-89 (2003).
11. Lujan R, Roberts JDB, Shigemoto R, Ohishi H, Somogyi P. Differential plasma membrane distribution of metabotropic glutamate receptors mGluR1alpha, mGluR2 and mGluR5, relative to neuro-transmitter release sites. J Chem Neuroanatom 13(4): 219-41 (1997).
12. Bortolotto ZA, Fitzjohn SM, Collingridge GL. Roles of metabotropic glutamate receptors in LTP and LTD in the hippocampus. Curr Opin Neurobiol 9: 299-304 (1999).
13. Storto M, de Grazia U, Knöpfel T, Canonico PL, Copani A, Richelmi P, et al. Selective blockade of mGlu5 metabotropic glutamate receptors protects rat hepatocytes against hypoxic damage Hepatology 31: 649-55 (2000).
14. Pacheco R, Ciruela F, Casadó V, Mallol J, Gallart T, Lluis C, et al. Group I metabotropic glutamate receptors mediate a dual role of glutamate in T cell activation. J Biol Chem 279: 33352-8 (2004).
15. Collard CD, Park KA, Montalto MC, Alapati S, Buras JA, Stahl GL, et al. Neutrophil-derived glutamate regulates vascular endothelial barrier function. J Biol Chem 277: 14801-11 (2002).
16. Porter RH, Jaeschke G, Spooren W, Ballard TM, Büttelmann B, Kolczewski S, et al. Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J Pharmacol Exp Ther 315(2): 711-21 (2005).
17. Vincent AM, TenBroeke M, Maiese K. Metabotropic glutamate receptors prevent programmed cell death through the modulation of neuronal endonuclease activity and intracellular Ph. Exp Neurol 155: 79-94 (1999).
18. Biber K, Laurie DJ, Berthele A, Sommer B, Tölle TR, Gebicke-Härter PJ, et al. Expression and signaling of group I metabotropic glutamate receptors in astrocytes and microglia. J Neurochem 72: 1671-80 (1999).
19. Lea PM, Custer SJ, Vicini S, Faden AI. Neuronal and glial mGluR5 modulation prevents stretch-induced enhancement of NMDA receptor current. Pharmacol Biochem Behav 73: 287-98 (2002).
20. O'Leary DM, Movsesyan V, Vicini S, Faden AI. Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamatemediated neuronal toxicity through actions that reflect NMDA receptor antagonism. Br J Pharmacol 131: 1429-37 (2000).
21. Bao WL, Williams AJ, Faden AI, Tortella FC. Selective mGluR5 receptor antagonist or agonist provides neuroprotection in a rat model of focal cerebral ischemia- Brain Res 922: 173-9 (2001).
22. Lea PM, Movsesyan VA, Faden AI. Neuroprotective activity of the mGluR5 antagonists MPEP and MTEP against acute excitotoxicity differs and does not reflect actions at mGluR5 receptors. Br J Pharmacol 145: 527-34 (2005).
23. Lee RK, Wurtman RJ, Cox AJ, Nitsch RM. Amyloid precursor protein processing is stimulated by metabotropic glutamate receptors. Proc Natl Acad Sci USA 15; 92(17): 8083-7 (1995).
24. Movsesyan VA, Stoica BA, Faden AI. mGLuR5 activation reduces [beta]-amyloid-induced cell death in primary neuronal cultures and attenuates translocation of cytochrome c and apoptosis-inducing factor. J Neurochem 89(6): 1528-36 (2004).
25. Minuzzia L, Quiriona R, Gauthiera S, Rosa-Netoa P. Declines of hippocampal metabotropic glutamate receptor in Alzheimer's disease. Alzheimer's Dementia 5(4) (Suppl 1): 267 (2009).
26. Casley CS, Lakics V, Lee HG, Broad LM, Day TA, Cluett T, et al. Up-regulation of astrocyte metabotropic glutamate receptor 5 by amyloid-beta peptide. Brain Res (2009); [Epub ahead of Print] [27] Oka A, Takashima S. The up-regulation of metabotropic glutamate receptor 5 (mGluR5) in Down's syndrome brains. Acta Neuropathol 97(3): 275-8 (1999).
27. Hagerman RJ, Hagerman PJ. Physical and behavioral phenotype. In: Hagerman RJ, Cronister A, Eds. Baltimore: John Hopkins University Press pp. 3-109 (2002).
28. Rudelli RD, Brown WT, Wisniewski K, Jenkins EC, Laure-Kamionowska M, Connell F, et al. Adult fragile X syndrome. Clinico-neuropathologic findings. Acta Neuropathol (Berl) 67: 289-95 (1985).
29. Wisniewski KE, Segan SM, Miezejeski CM, Sersen EA, Rudelli RD. The Fra(X) syndrome: Neurological, electrophysiological, and neuropathological abnormalities. Am J Med Genet 38: 476-80 (1991).
30. Engert F, Bonhoeffer T. Dendritic spine changes associated with hippocampal long-term synaptic plasticity. Nature 399: 66-70 (1999).
31. Huber KM, Gallagher SM, Warren ST, Bear MF. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci USA 99: 7746-50 (2002).
32. Zhang J, Hou L, Klann E, Nelson DL. Altered hippocampal synaptic plasticity in the FMR1 gene family knockout mouse models. J Neurophysiol 101(5): 2572-80 (2009).
33. Shang Y, Wang H, Mercaldo V, Li X, Chen T, Zhuo M. Fragile X mental retardation protein is required for chemically-induced long-term potentiation of the hippocampus in adult mice. J Neurochem 111(3): 635-46 (2009).
34. Tackenberg C, Ghori A, Brandt R. Thin, stubby or mushroom: spine pathology in Alzheimer's disease. Curr Alzheimer Res 6(3): 261-8 (2009).
35. Verkerk AJ, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DP, Pizzuti A, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65: 905-14 (1991).
36. Oberle I, Rousseau F, Heitz D, Kretz C, Devys D, Henauer A, et al. Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science 252: 1097-102 (1991).
37. Bagni C, Greenough WT. From mRNP trafficking to spine dysmorphogenesis: The roots of fragile X syndrome. Nat Rev Neurosci 6: 376-87 (2005).
38. Cheever A, Ceman S. Phosphorylation of FMRP inhibits association with Dicer. RNA 15(3): 362-6 (2009).
39. Zalfa F, Giorgi M, Primerano B, Moro A, Di Penta A, Reis S, et al. The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses. Cell 112: 317-27 (2003).
40. Laggerbauer B, Ostareck D, Keidel EM, Ostareck-Lederer A, Fischer U. Evidence that fragile X mental retardation protein is a negative regulator of translation. Hum Mol Genet 10: 329-38 (2001).
41. Darnell JC, Jensen KB, Jin P, Brown V, Warren ST, Darnell RB, et al. Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function. Cell 107: 489-99 (2001).
42. Chen L, Yun SW, Seto J, Liu W, Toth M. The fragile X mental retardation protein binds and regulates a novel class of mRNAs containing U rich target sequences. Neuroscience 120: 1005-17 (2003).
43. Ule J, Jensen KB, Ruggiu M, Mele A, Ule A, Darnell RB. CLIP identifies Nova-regulated RNA networks in the brain. Science 302: 1212-1215 (2003).
44. Bassell GJ, Warren ST, Fragile X. Syndrome: loss of local mrna regulation alters synaptic development and function. Neuron 60(2): 201-14 (2008).
45. Todd P, Mack K, Malter JS. The fragile X mental retardation protein is required for type-I metabotropic glutamate receptor dependent translation of PSD-95. Proc Natl Acad Sci USA 100: 14374-8 (2003).
46. Greenough WT, Klintsova AY, Irwin SA, Galvez R, Bates KE, Weiler IJ, et al. Synaptic regulation of protein synthesis and the fragile X protein. Proc Natl Acad Sci USA 98: 7101-6 (2001).
47. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci 27: 370-7 (2004).
48. Berry-Kravis E, Hessl D, Coffey S, Hervey C, Schneider A, Yuhas J, et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet 46(4):266-71 (2009).
49. de Vrij FM, Levenga J, van der Linde HC, Koekkoek SK, De Zeeuw CI, Nelson DL, et al. Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis 31(1): 127-32 (2008).
50. Westmark CJ, Westmark PR, Malter JS. MPEP Reduces Seizure Severity in Fmr-1 KO mice over Expressing Human Abeta. Int J Clin Exp Pathol 10; 3(1): 56-68 (2009).
51. Schaeffer C, Bardoni B, Mandel JL, Ehresmann B, Ehresmann C, Moine H, et al. The fragile X mental retardation protein binds specifically to its mRNA via a purine quartet motif. EMBO J 20: 4803-13 (2001).
52. Denman R, Potempska A, Wolfe G, Ramakrishna N, Miller DL. Distribution and activity of alternatively spliced Alzheimer amyloid peptide precursor and scrapie PrP mRNAs on rat brain polysomes. Arch Biochem Biophys 288: 29-38 (1991).
53. Sung YJ, Weiler IJ, Greenough WT, Denman RB. Selectively enriched mRNAs in rat synaptoneurosomes. Brain Res Mol Brain Res 126: 81-7 (2004).
54. Westmark CJ, Malter JS. FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol 5(3): e52 (2007).
55. D'Agata V, Warren ST, Zhao W, Torre ER, Alkon DL, Cavallaro S, et al. Gene expression profiles in a transgenic animal model of fragile X syndrome. Neurobiol Dis 10: 211-8 (2002).
56. Wållberg A, Nilsson K, Osterlund K, Peterson A, Elg S, Raboisson P, et al. Phenyl ureas of creatinine as mGluR5 antagonists. A structure-activity relationship study of fenobam analogues. Bioorg Med Chem Lett 16(5): 1142-5 (2006).
57. Jacob W, Gravius A, Pietraszek M, Nagel J, Belozertseva I, Shekunova E. The anxiolytic and analgesic properties of fenobam, a potent mGlu5 receptor antagonist, in relation to the impairment of learning. Neuropharmacology doi:10.1016/j.neuropharm.2009.04. 011 (2009).
58. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, A elevation, and amyloid plaques in transgenic mice. Science 274: 99-102 (1996).
59. Lamb BT, Call LM, Slunt HH, Bardel KA, Lawler AM, Eckman CB, et al. Altered metabolism of familial Alzheimer's disease linked amyloid precursor protein variants in yeast artificial chromosome transgenic mice. Hum Mol Genet 6: 1535-41 (1997).